Financial Data and Key Metrics Changes - Revenues for Q3 2026 were $16.3 million, up from $12.4 million in the previous quarter but down from $40.7 million in the same quarter last year, primarily due to the absence of theatrical results from "Terrifier 3" which generated over $20 million in the prior year [13] - The net loss for the quarter was $875,000, a $4.7 million improvement over the prior quarter [13] - Adjusted EBITDA for the quarter was $2.4 million, reflecting a $6 million improvement from the previous quarter [13] - Direct operating margin improved to 69%, up from 48% in the prior year quarter [6][20] Business Line Data and Key Metrics Changes - The company focused on improving its cost structure and operating margins in its base businesses, achieving a direct operating margin of 69% [6][20] - The acquisitions of Giant Worldwide and IndiCue are expected to significantly enhance revenue streams and profitability, with projected contributions of over $50 million in revenue and $10 million in Adjusted EBITDA for fiscal year 2027 [17][18] Market Data and Key Metrics Changes - The streaming ecosystem saw a monthly unique viewer count of 35.5 million, with SVOD subscribers growing 15% year-over-year to 1.55 million [19] - The content library now exceeds 66,000 total assets, including nearly 58,000 films and over 8,500 podcasts [19] Company Strategy and Development Direction - The company aims to transform into a comprehensive, AI-powered technology services provider for the entertainment industry through the acquisitions of Giant and IndiCue [5][8] - The strategy focuses on addressing the fragmented nature of content distribution and monetization, leveraging AI to enhance operational efficiency and scalability [21][28] - The market opportunity in post- and media services is projected to grow from $25 billion to $74 billion by 2034, with a shift towards AI-powered workflows [24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the financial guidance for fiscal year 2027, projecting revenues of $115 million to $120 million and Adjusted EBITDA of $10 million to $20 million [11][17] - The integration of Giant and IndiCue is expected to create significant shareholder value and improve operational efficiencies [18][28] - Management highlighted the importance of building a unified, automated architecture for the entire media supply chain to meet future market demands [29] Other Important Information - The company sold 1.725 million shares of common stock at $2 per share, generating net proceeds of $3.2 million for working capital and content acquisition [18] - The acquisitions were financed with convertible notes from long-term shareholders, reflecting strong investor confidence in the company's strategy [17] Q&A Session Summary Question: Can you discuss the evolution of IndiCue's business and its revenue concentration? - Management noted that IndiCue's revenue concentration has improved year-over-year, with a focus on building durable relationships with major clients [33][36] Question: What is the significance of the new customers announced for Matchpoint? - Management indicated that the acquisition of Giant has allowed for expedited access to major studios, enhancing the ability to sell additional Matchpoint services [39][44] Question: What are the anticipated synergies from the acquisitions? - Management expects significant revenue synergies from both acquisitions, with potential for $8 million to $9 million in synergies from IndiCue alone [51][56] Question: How will free cash flow be managed moving forward? - Management emphasized that free cash flow will be reinvested into growth initiatives rather than through dilution, positioning the company for future acquisitions [66] Question: What is the company's future M&A strategy? - Management stated that while the focus is currently on integrating the recent acquisitions, they remain open to pursuing additional opportunities that align with their strategic goals [84][85]

Glaukos (NYSE:GKOS) Q4 2025 Earnings call February 17, 2026 04:30 PM ET Speaker11Hello, and thank you for standing by. My name is Tiffany, and I will be your conference operator today. At this time, I would like to welcome everyone to Glaukos's fourth quarter and full year 2025 financial results conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during that time, si ...

Financial Data and Key Metrics Changes - For the full year 2025, Beta Bionics reported net sales of $100.3 million, representing a 54% year-over-year growth. The gross margin was 55.4%, which expanded slightly year-over-year [10][11] - In Q4 2025, the company generated $32.1 million in net sales, reflecting a 57% growth year-over-year, with a gross margin of 59%, an increase of 179 basis points year-over-year [11][12] Business Line Data and Key Metrics Changes - The company added approximately 20,000 new users in 2025, more than doubling its installed base to over 35,000 users [6][10] - In Q4, 5,592 new patient starts were recorded, a 37% increase year-over-year, with a growing percentage of new patient starts reimbursed through the pharmacy channel [11][12] Market Data and Key Metrics Changes - The percentage of new patient starts through the pharmacy channel grew to the high 20s% for the full year 2025, compared to a high single-digit percentage in the previous year [10][12] - In Q4, approximately 69% of new patient starts came from individuals who previously used multiple daily injections, indicating an expansion of the market for insulin pumps [16] Company Strategy and Development Direction - Beta Bionics aims to revolutionize diabetes care by improving access and outcomes for people with diabetes through innovative products like the iLet and the upcoming Mint patch pump [5][9] - The company has established formulary agreements with major pharmacy benefit managers, enhancing user access to the iLet and its consumables at lower out-of-pocket costs [8][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to continue expanding the pump market and capturing market share, with revenue guidance for 2026 set at $130 million to $135 million [18][19] - The company acknowledged challenges related to seasonality in the insulin pump market, particularly the expected decline in Q1 2026 revenue compared to Q4 2025 [21][23] Other Important Information - The company received a Warning Letter from the FDA regarding quality system observations, which management is actively addressing through remediation efforts [29][30] - Beta Bionics is progressing with its R&D initiatives, including the development of the Mint patch pump and the bihormonal system, with significant milestones achieved in clinical trials [40][41] Q&A Session Summary Question: Can you discuss the level of conservatism in the 2026 guidance? - Management refrained from labeling the guidance as conservative but expressed confidence in meeting the communicated revenue targets, considering potential headwinds from pharmacy channel performance [46][47] Question: What is the outlook for the U.S. pump market in Q4? - Management did not provide specific insights on market share due to competitors not yet reporting their earnings [53][55] Question: How will the expansion of sales territories impact market coverage? - The company plans to add at least 20 new sales territories in 2026, with a significant portion of this expansion occurring in the first half of the year [56][60] Question: What are the expectations for Q1 2026 revenue? - Management indicated that Q1 2026 is expected to see a larger decline in revenue compared to the previous year, influenced by unique product launches in Q4 2024 [63][68] Question: How does the company address concerns regarding hypoglycemia? - Management stated that the rates of hypoglycemia with the iLet are consistent with clinical trials and significantly lower than ADA guidelines, emphasizing the safety of their product [85][86]

AtriCure (NasdaqGM:ATRC) Q4 2025 Earnings call February 17, 2026 04:30 PM ET Speaker10Good afternoon, and welcome to AtriCure's fourth quarter and full year 2025 earnings conference call. This call is being recorded for replay purposes, and at this time, all participants are in listen-only mode. We will be facilitating a question-and-answer session following prepared remarks from AtriCure's management. I would now like to turn the call over to Marissa Bych from the Gilmartin Group for a few introductory com ...

TechPrecision (NasdaqCM:TPCS) Q3 2026 Earnings call February 17, 2026 04:30 PM ET Speaker3Greetings, and welcome to the TechPrecision Corporation Fiscal 2026 third quarter financial results. At this time, all participants are placed on a listen-only mode. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Mr. Brett Maas, Managing Director of Hayden IR. Thank you, sir. You may begin.Speaker1Thank you. On the call today is Alex Shen, Chief Executive Officer, and Ph ...

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $105.3 million, up 12% year-over-year, and $365.3 million for the full year, growing 16% [28] - Adjusted EBITDA for Q4 grew 5% to $39.2 million, with a full year adjusted EBITDA of $113.6 million, growing 14% and producing an adjusted EBITDA margin of 31% [31] - Total written premiums for Q4 were $1.1 billion, growing 13% year-over-year, and $4.4 billion for the full year, up 17% over 2024 [30] Business Line Data and Key Metrics Changes - Core revenues for Q4 grew 15% to $78.2 million, and for the full year, they grew 16% to $317.9 million due to improved client retention and new business production [28] - Policies in force grew 14% to 1.9 million, accelerating from a 13% growth rate in Q3 2025 [31] - Gross payments per franchise increased by 29% year-over-year, indicating improved cash flow for franchise owners [9] Market Data and Key Metrics Changes - The company is transitioning from a hard market to a healthier product market, which is expected to enhance growth opportunities [7] - The corporate agents outside of Texas increased from 30% in 2022 to 52% in 2025, indicating geographic expansion [11] - The enterprise sales and partnership network almost doubled new business production in 2025, addressing millions of mortgages serviced across the country [11] Company Strategy and Development Direction - The company aims to accelerate growth within existing agencies, expand corporate sales, and invest in technology, particularly AI applications [16] - Goosehead is focused on maintaining a long-term mindset and prioritizing quality over quantity in its franchise network [19] - The Digital Agent 2.0 platform is a key strategic initiative, providing an end-to-end choice buying experience and enhancing client interactions [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's position for 2026, anticipating low double-digit core revenue growth in the first half and acceleration in the second half [29] - The company acknowledges the evolving nature of insurance distribution due to technology advancements but remains committed to its core business model [12] - Management highlighted the importance of client retention and the positive impact of technology on service efficiency [26] Other Important Information - The company repurchased and retired 323,000 shares of Class A stock in Q4, representing $22.5 million, with an additional $180 million share repurchase authorization approved [33] - Cash flow from operations for the year was $91.8 million, up 28% from the prior year [32] - The company is investing heavily in technology to enhance its competitive advantage and improve client experience [12] Q&A Session Summary Question: How is the company thinking about home closing transactions and the insurance pricing environment for next year? - Management noted that housing construction has not been a significant headwind and that they are not counting on improvements in housing for guidance in 2026 [37] - Pricing dynamics are expected to vary, with the bottom end of guidance including generally down pricing and the top end reflecting moderate increases [38] Question: How would regulatory changes like profitability caps impact the business model? - Management indicated that such changes could affect carrier appetite and commission economics, but the impact remains uncertain [40] Question: Why does the company believe agents will not be disintermediated through AI? - Management emphasized the complexity of home insurance sales and the continued demand for human guidance, suggesting that AI will enhance agent productivity rather than replace them [44][46] Question: How is the Digital Agent 2.0 platform performing in terms of customer retention? - Initial results show that existing clients are using the platform to purchase additional policies, which is expected to improve client retention [49] Question: What is the company's outlook on buybacks given the current stock valuation? - Management expressed a strong appetite for buybacks, citing the undervaluation of the stock and the strong cash flow generation capabilities [58]

RB Global (NYSE:RBA) Q4 2025 Earnings call February 17, 2026 04:30 PM ET Speaker8Hello, everyone. Thank you for joining us, and welcome to the RB Global Fourth Quarter 2025 Earnings Call. After today's prepared remarks, we will host a question and answer session. If you would like to ask a question, please press star one on your telephone keypad. To withdraw your question, press star one again. I will now hand the call over to Sameer Rathod, Vice President, Investor Relations and Market Intelligence. Please ...

Financial Data and Key Metrics Changes - Total revenue grew 38% to $1.4 billion, with royalty revenue increasing 52% to $868 million for the full year 2025 [7][15][17] - Net income for the full year was $316.9 million, compared to $444.1 million reported in 2024 [17] - Adjusted EBITDA was $657.6 million, compared to $632.2 million in 2024 [17] - GAAP diluted EPS was $2.50, compared with $3.43 in 2024, while non-GAAP diluted EPS was $4.15, compared with $4.23 in 2024 [17][18] Business Line Data and Key Metrics Changes - DARZALEX Subcutaneous generated $483 million in royalty revenues, representing 29% year-over-year growth, with total sales growing 22% to $14.4 billion [8][9] - PHESGO delivered $105.6 million in royalty revenue, reflecting 51% year-over-year growth, with total sales increasing 48% to approximately $3 billion [9][10] - VYVGART and VYVGART Hytrulo generated $157.2 million in royalty revenue, representing 444% year-over-year growth, with total sales growing 90% to $4.15 billion [10][11] Market Data and Key Metrics Changes - The company now has 10 ENHANZE-enabled global blockbuster opportunities, with significant approvals in the U.S., Japan, and China [6][12] - Roche reported that there are now 17,500 patients on Ocrevus Zunovo, a 5,000 patient increase from the third quarter [11] - Analysts project that PHESGO will reach CHF 3.6 billion in 2028, and Ocrevus franchise sales expectations have been increased to CHF 9 billion, or approximately $11.5 billion [10][12] Company Strategy and Development Direction - The company expanded its portfolio from two to four subcutaneous drug delivery technologies through acquisitions, positioning itself as a one-stop shop for biopharma subcutaneous drug delivery [5][6] - The focus is on advancing the ENHANZE pipeline, with projections for 6 new ENHANZE programs entering phase one in 2026 [21][32] - The company aims to continue strategic M&A to enhance its drug delivery portfolio and maintain financial discipline while investing in long-term value creation [24][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term trajectory of the company, highlighting multiple revenue drivers that will support durable royalty revenue [20][36] - The company anticipates continued strong growth from its existing blockbusters and new product launches, with a focus on expanding into new therapeutic areas [20][21] - Management expects to enter discussions with Johnson & Johnson to extend the DARZALEX collaboration agreement closer to its expiration in 2032 [39][40] Other Important Information - The company signed three new ENHANZE collaboration and licensing agreements, expanding its reach beyond oncology into obesity and inflammatory bowel disease [6][7] - The acquisition of Surf Bio is expected to enhance the company's hyperconcentration technology capabilities [24] - The company ended the year with a net debt to EBITDA ratio of 2.1x, with expectations to deleverage to below 1x by the end of 2026 [19] Q&A Session Summary Question: Can you elaborate on the mechanics of the DARZALEX collaboration with J&J? - Management expects to enter discussions with J&J to extend the agreement closer to its expiration in 2032, as they do not anticipate J&J seeking another source of API [39][40] Question: What are the regulatory paths for ADCs with ENHANZE? - The regulatory pathway for converting from IV to subcutaneous is expected to follow traditional PK non-inferiority studies, while additional benefits would require phase trials [46][47] Question: What is the progress on Hypercon products? - The company is on track to support two partners in advancing to phase 1 clinical testing in 2026, with clinical scale-up batches being completed [61][62] Question: How will sales from auto-injectors be reported? - Sales from auto-injectors will be recognized similarly to API sales, with royalties recognized on commercial sales [76]

cbdMD (NYSEAM:YCBD) Q1 2026 Earnings call February 17, 2026 04:20 PM ET Company ParticipantsBrad Whitford - Chief Accounting Officer, Treasurer, and SecretaryRonan Kennedy - CEO and CFOThomas McGovern - Equity Research AssociateOperatorGood afternoon. Welcome, ladies and gentlemen, to cbdMD, Inc.'s December 31st, 2025, First Fiscal Quarter of 2026 earnings call and update. This afternoon, the company issued a press release that provided an overview of its first quarter results, which followed the filing of ...

Financial Data and Key Metrics Changes - For the first quarter of fiscal 2026, net sales totaled $5 million, a 12% sequential increase from the fourth quarter of fiscal 2025, but a slight decrease from $5.1 million in the prior year period [12] - Gross margin decreased to 60% from 66% in the prior year, primarily due to increased warehouse expenses and a shift in revenue mix towards wholesale [12] - Net loss attributable to common shareholders improved to approximately $325,000, or $0.04 per share, compared to a net loss of approximately $1 million, or $1.73 per share in the prior year quarter [13] Business Line Data and Key Metrics Changes - Direct-to-consumer sales represented approximately 72% of total revenue, while wholesale business accounted for 28% of revenue, showing a year-over-year growth of 17% [5] - The wholesale growth reflects improved execution in the core cbdMD brand and ongoing progress with the beverage brand, Oasis [5] Market Data and Key Metrics Changes - The company reported three consecutive quarters of sequential revenue growth, indicating positive trends in the business despite a challenging regulatory environment [4] - December 2025 and January 2026 marked the highest monthly revenue levels since 2022, suggesting a recovery in core business performance [4] Company Strategy and Development Direction - The company is focused on reducing fixed costs, simplifying operations, and strengthening the balance sheet to position for regulated growth [5] - The acquisition of Bluebird Botanicals is seen as strategically important, adding incremental revenue and a loyal customer base, while also enhancing regulatory and scientific positioning [7][8] - The company aims to maintain separate brand identities for Bluebird and cbdMD to cater to different customer bases [22] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the long-term runway supported by a strong cash position and the incremental benefits from the Bluebird acquisition [15] - The regulatory environment remains uncertain, but recent bipartisan efforts to revisit restrictive hemp legislation are viewed positively [10] - The company is focused on generating positive EBITDA and managing cash carefully to support sustainable operating results [14] Other Important Information - The company completed approximately $2.25 million in Series C Preferred financing, strengthening liquidity and working capital [9] - As of December 31, 2025, cash and cash equivalents increased to approximately $3.4 million, reflecting improved liquidity [14] Q&A Session Summary Question: Insights on the integration of Bluebird Botanicals - Management indicated that they have brought over some team members from Bluebird and see opportunities for growth by leveraging their expertise and improving marketing activities [19] Question: Plans for integrating e-commerce capabilities - The company intends to maintain Bluebird as a separate brand due to differences in customer bases, allowing for continued growth [22] Question: Contribution of the Oasis line of seltzers to sales - While Oasis is starting to contribute, it remains small relative to the overall size of the core cbdMD brand, with expectations for improvement throughout the year [24]